anurajms/meta_analysis huggingface dataset:
outcomes:
Bisphosphonates in multiple myeloma: an updated network meta‐analysis
1. Skeletal Injury NOS 2. Pain 3. Overall Survival 4. Progression-Free Survival 5. Death 6. Aseptic Necrosis Of Bone Of Jaw
outcomes:
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients with solid tumours
1. Death 2. Haemorrhage
outcomes:
Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease
1. Death 2. Acute Sickle Cell Splenic Sequestration Crisis
outcomes:
Hematopoietic stem cell transplantation for Gaucher disease
1. Platelet Count 2. Morbidity Index 3. Hemopoietic Stem Cell Transplant 4. Spleen Finding 5. Death 6. Liver Finding 7. Hemoglobin concentration
outcomes:
Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn
1. All Cause Mortality 2. Cardiac Arrhythmia 3. Apnea 4. Cardiac Arrest 5. Hypoglycemia 6. Serum Calcium
outcomes:
Thrombopoietin mimetics for patients with myelodysplastic syndromes
1. Death
outcomes:
Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation
1. Serious Adverse Event 2. Haemorrhage
outcomes:
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
1. Hemarthrosis 2. Quality of Life 3. Haemorrhage 4. Adverse Event
outcomes:
Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression‐free survival: individual participant data analysis
1. Adverse Event
outcomes:
Deferasirox for managing iron overload in people with thalassaemia
1. Renal Failure 2. Ferritin level 3. Death 4. Increased Serum Creatinine 5. Liver Finding 6. Patient Satisfaction
outcomes:
Fluid replacement therapy for acute episodes of pain in people with sickle cell disease
1. Pain
outcomes:
Pathogen‐reduced platelets for the prevention of bleeding
1. All Cause Mortality 2. Haemorrhage
outcomes:
Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
1. Hodgkins Lymphoma 2. Acute Myelocytic Leukemia 3. Adverse Drug Reaction 4. Treatment Related Secondary Malignancy 5. Myelodysplastic Syndrome 6. Disease Progression 7. Infertility 8. Quality of Life 9. Death 10. Secondary Amenorrhea
outcomes:
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
1. Overall Survival 2. Death
outcomes:
Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
1. Heparin-induced Thrombocytopenia
outcomes:
Exercise for haemophilia
1. Finding Of Balance 2. Pain 3. 6-minute Walk Test 4. Range Of Motion Testing 5. Quality of Life 6. Visual Analog Scale 7. Joint Finding 8. Haemorrhage 9. Functional ability 10. Adverse Event 11. Pain Intensity
outcomes:
Antibiotics for treating community‐acquired pneumonia in people with sickle cell disease
1. Pneumonia 2. Treatment Success 3. Death 4. Time-to-Event
outcomes:
Hydroxyurea for reducing blood transfusion in non‐transfusion dependent beta thalassaemias
1. Thrombocytopenia 2. Neutropenic Disorder 3. Blood Transfusion 4. Quality of Life 5. Hereditary Persistence Of Fetal Hemoglobin Thalassemia 6. Adverse Event 7. Hemoglobin Finding 8. Mean Cell Hemoglobin Level
outcomes:
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review
1. Adverse Drug Reaction 2. All Cause Mortality 3. Red Blood Cell Transfusion 4. Platelet transfusion 5. Haemorrhage 6. Thromboembolism 7. Transfusion Reaction
outcomes:
Bisphosphonate therapy for osteogenesis imperfecta
1. Bone Density 2. Fracture 3. Reduction Of Fracture
outcomes:
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications
1. Patient knowledge 2. Interpersonal Relationship Observations 3. Self-care Behavior 4. Depression 5. Duration Of Hospital Stay 6. Hospitalization 7. Ability to cope 8. Hemoglobin SS Disease 9. Health Care Utilization 10. Patient-Reported Outcome 11. Carer-Reported Outcome
outcomes:
Bortezomib for the treatment of multiple myeloma
1. Overall Survival 2. Progression-Free Survival 3. Death
outcomes:
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders
1. Antifibrinolytics 2. All Cause Mortality 3. Adverse Drug Reaction 4. Quality of Life 5. Platelet transfusion 6. Thromboembolism 7. Haemorrhage 8. Transfusion Reaction
outcomes:
Subsidising artemisinin‐based combination therapy in the private retail sector
1. Artemisinin and derivatives combinations 2. Adverse Event
outcomes:
Oral iron supplements for children in malaria‐endemic areas
1. All Cause Mortality 2. Malaria 3. Death 4. Hospitalization
outcomes:
Granulocyte and granulocyte‐macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes
1. Infection 2. Blood Transfusion 3. Serious Adverse Event 4. Progression-Free Survival 5. Overall Survival 6. Quality of Life 7. Death 8. Time-to-Event 9. Transformation to acute myeloid leukaemia
outcomes:
Piracetam for reducing the incidence of painful sickle cell disease crises
1. Pain 2. Opioids 3. Sickle Cell Crisis 4. Pain Intensity
outcomes:
Meditation for adults with haematological malignancies
1. Poor Quality Sleep 2. Quality of Life 3. Death 4. Fatigue 5. Depression 6. Anxiety 7. Adverse Event
outcomes:
Washed versus unwashed red blood cells for transfusion for the prevention of morbidity and mortality in preterm infants
1. Chronic Lung Disease 2. Intraventricular Hemorrhage 3. Hydrocephalus 4. Hearing impairment 5. Cerebral Atrophy 6. Necrotizing Enterocolitis 7. Developmental Delay 8. Periventricular Leukomalacia 9. Adverse Event 10. Oxygen Supplementation 11. Retinopathy Of Prematurity 12. Blindness 13. Death 14. Cerebral Palsy
outcomes:
Antibody therapies for lymphoma in children
1. Malignant Lymphoma In Remission 2. Relapse 3. Event-Free Survival 4. Overall Survival 5. Adverse Event
outcomes:
Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
1. Quality of Life 2. Terminal State
outcomes:
Low‐molecular‐weight heparins for managing vaso‐occlusive crises in people with sickle cell disease
1. Pain 2. Opioids 3. Quality of Life 4. Complication 5. Hospitalization 6. Adverse Event 7. Hemoglobin SS Disease 8. Patient Satisfaction
outcomes:
Recombinant factor VIIa concentrate versus plasma‐derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors
1. Pain 2. Hematoma 3. Haemorrhage
outcomes:
Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia
1. All Cause Mortality 2. Post Procedural Bleeding 3. Haemorrhage
outcomes:
Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Platelet transfusion 2. Haemorrhage
outcomes:
Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission
1. Hypersensitivity Condition 2. Relapse 3. Acute myeloid leukaemia (in remission) 4. Chill 5. Joint Pain 6. Rigor 7. Fatigue 8. Myalgia 9. Disease-Free Survival 10. Disease Progression 11. Overall Survival 12. Quality of Life 13. Death
outcomes:
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. Haemorrhage
outcomes:
Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma
1. Graft Acceptance 2. Overall Survival 3. Progression-Free Survival 4. Quality of Life 5. Stem cell collecton 6. Adverse Event
outcomes:
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders
1. Infection 2. All Cause Mortality 3. Non-urgent Hospital Admission 4. Iron Excess 5. Quality of Life 6. Death 7. Duration Of Hospital Stay 8. Common Terminology Criteria For Adverse Events 9. Haemorrhage 10. Transfusion Reaction
outcomes:
A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
1. All Cause Mortality 2. Quality of Life 3. Platelet transfusion 4. Haemorrhage
outcomes:
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia
1. Acute Myelocytic Leukemia 2. Disease-Free Survival 3. Relapse 4. Acute myeloid leukaemia (in remission) 5. Overall Survival 6. Quality of Life 7. Death 8. Cardiotoxicity
outcomes:
Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell transplantation
1. Overall Survival 2. Quality of Life 3. Death 4. Veno-occlusive Disease Of The Liver 5. Adverse Event
outcomes:
Psychological therapies for sickle cell disease and pain
1. Pain 2. Mood 3. Hospitalization 4. Ability to cope 5. Health Care Utilization
outcomes:
Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis
1. Adverse Drug Reaction 2. Overall Survival 3. Progression-Free Survival 4. Death 5. Adverse Event
outcomes:
Sapropterin dihydrochloride for phenylketonuria
1. Finding Of Phenylalanine Level
outcomes:
Enzyme replacement and substrate reduction therapy for Gaucher disease
1. Adverse Drug Reaction 2. Platelet Count 3. Spleen Finding 4. Hepatosplenomegaly 5. Liver Finding 6. Hemoglobin concentration
outcomes:
Protein substitute for children and adults with phenylketonuria
1. Body Mass Index 2. Neuropsychological Testing 3. Growth 4. Weight Gain 5. Nutritional status
outcomes:
Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria
1. Treatment Failure 2. Polymerase Chain Reaction
outcomes:
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery
1. Death 2. Haemorrhage
outcomes:
Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma
1. Overall Survival
outcomes:
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Serious Adverse Event 3. Transfusion 4. Overall Survival 5. Death 6. Fatigue 7. Adverse Event 8. Health-Related Quality of Life
outcomes:
Deferasirox for managing iron overload in people with myelodysplastic syndrome
1. Overall Survival
outcomes:
Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
1. Infant Death 2. Birth Weight 3. Malaria 4. Anemia 5. Stillbirth 6. Neonatal Death 7. Perinatal Death 8. Maternal Death 9. Adverse Event 10. Preterm Infant 11. Hemoglobin concentration 12. Blood loss anaemia neonatal 13. Placental Malaria 14. Parasitemia
outcomes:
Interventions for treating acute bleeding episodes in people with acquired hemophilia A
1. Haemorrhage
outcomes:
Mycophenolate mofetil versus methotrexate for prevention of graft‐versus‐host disease in people receiving allogeneic hematopoietic stem cell transplantation
1. Narcotic Drug User 2. Relapse 3. Acute Mucositis 4. Overall Survival 5. Death 6. Graft Versus Host Disease 7. Total Parenteral Nutrition 8. Pain Control
outcomes:
The role of additional radiotherapy for primary central nervous system lymphoma
1. Overall Survival
outcomes:
Deferasirox for managing transfusional iron overload in people with sickle cell disease
1. All Cause Mortality
outcomes:
Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria
1. Treatment Failure 2. Polymerase Chain Reaction
outcomes:
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
1. Serious Adverse Event 2. Parasitemia 3. Adverse Event
outcomes:
Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria
1. Serious Adverse Event 2. Preventative intervention 3. Malaria 4. Parasitemia 5. Parasite Blood Test Positive 6. Fever
outcomes:
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment
1. All Cause Mortality 2. Disease Recurrence 3. Recurrent Disease 4. Recurrence free survival
outcomes:
Hyperbaric oxygen therapy for late radiation tissue injury
1. Death 2. Late Effect Of Injury 3. Complete response
outcomes:
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
1. Overall Survival 2. Poisoning 3. Adverse Event 4. Health-Related Quality of Life
outcomes:
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
1. Stomatitis 2. Disease Progression 3. Progression-Free Survival 4. Overall Survival 5. Hand-Foot Syndrome 6. Death 7. Hair loss 8. Toxicity Due To Chemotherapy 9. Withdrawal Due To Adverse Events
outcomes:
Local versus radical surgery for early rectal cancer with or without neoadjuvant or adjuvant therapy
1. Disease-Free Survival 2. Urethral Sphincter Function
outcomes:
Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery
1. Postoperative Complication 2. 6-minute Walk Test 3. Functional ability 4. Health-Related Quality of Life 5. Patient-Reported Outcome
outcomes:
First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis
1. Serious Adverse Event 2. Overall Survival 3. Quality of Life
outcomes:
Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
1. Death
outcomes:
Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk
1. Death 2. Breast Cancer
outcomes:
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer
1. Death 2. Adverse Event
outcomes:
Skin‐sparing mastectomy for the treatment of breast cancer
1. Death
outcomes:
Exercise interventions for adults with cancer receiving radiation therapy alone
1. Functional Assessment Measure 2. Fatigue
outcomes:
Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
1. Prostate Cancer 2. Adverse Event 3. Survival
outcomes:
Preoperative combined mechanical and oral antibiotic bowel preparation for preventing complications in elective colorectal surgery
1. Postoperative Complication 2. Surgical Site Infection 3. Postoperative Ileus 4. Length Of Stay 5. Death 6. Adverse Event 7. Anastomotic leak
outcomes:
Corticosteroids for the management of cancer‐related fatigue in adults with advanced cancer
1. Visual Analog Fatigue Scale 2. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 3. Profile of Mood States Fatigue susbscale 4. Serious Adverse Event 5. Functional Assessment of Chronic Illness Therapy-Fatigue 6. Brief Fatigue Inventory 7. Quality of Life 8. Edmonton symptom assessment system 9. Fatigue 10. SF-36 Vitality Subscale 11. Adverse Event
outcomes:
Neoadjuvant treatment for stage III and IV cutaneous melanoma
1. Overall Survival 2. Common Terminology Criteria For Adverse Events 3. Adverse Event
outcomes:
Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer
1. Death 2. Adverse Event
outcomes:
Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer
1. Death
outcomes:
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation
1. Cognitive function
outcomes:
Preoperative exercise training for people with non‐small cell lung cancer
1. Postoperative Complication 2. Catheter 3. Length Of Stay 4. Exercise Capacity 5. Adverse Event
outcomes:
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
1. Heart Failure 2. Death
outcomes:
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer
1. Surgical complication 2. Death
outcomes:
Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care
1. Laxation response 2. Analgesia 3. Serious Adverse Event
outcomes:
Ultra‐radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer
1. Overall Survival 2. Death
outcomes:
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer
1. Death
outcomes:
Impact of low‐dose computed tomography (LDCT) screening on lung cancer‐related mortality
1. Lung cancer 2. Harmful effects of screening
outcomes:
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
1. Death 2. Clinical Improvement
outcomes:
Oxycodone for cancer‐related pain
1. Vomiting 2. Quality of Life 3. Nausea 4. Sleepiness 5. Constipation 6. Pain Relief 7. Pain Intensity
outcomes:
Perioperative enhanced recovery programmes for women with gynaecological cancers
1. Postoperative Complication 2. Hospital discharge 3. Death
outcomes:
Gases for establishing pneumoperitoneum during laparoscopic abdominal surgery
1. Analgesia 2. Pain 3. Cardiac Complication 4. Costs and Cost Analysis 5. Serious Adverse Event 6. Pain Scale 7. Pneumoperitoneum 8. Quality of Life 9. Death 10. Complication
outcomes:
Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer
1. Neutropenic Disorder 2. Death
outcomes:
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
1. Death
outcomes:
Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy
1. Postoperative Hemorrhage 2. Delayed Gastric Emptying 3. Pancreatic Fistula 4. Repeat surgery 5. Quality of Life 6. Death 7. Duration Of Hospital Stay 8. Intra-abdominal fluid collection
outcomes:
Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Aromatase Inhibitors
outcomes:
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
1. Progression-Free Survival 2. Death 3. Adverse Event 4. Therapeutic Response 5. Health-Related Quality of Life
outcomes:
Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Assessment Of Quality Of Life 3. Hospital Anxiety And Depression Scale 4. Edmonton symptom assessment system 5. Depression 6. Death 7. Anxiety 8. Symptom control therapy 9. Beck Depression Inventory
outcomes:
Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
1. Recurrent Tumor 2. Death 3. Locoregional Progression
outcomes:
Prophylactic abdominal drainage for pancreatic surgery
1. Costs and Cost Analysis 2. Morbidity Index 3. Pain 4. Abdominal Infection 5. Quality of Life 6. Length Of Stay 7. Death 8. Wound Infection
outcomes:
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
1. Serious Adverse Event 2. Overall Survival 3. Progression-Free Survival 4. Adverse Event 5. Therapeutic Response 6. Health-Related Quality of Life
outcomes:
Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer
1. Disease Recurrence 2. Disease Progression 3. Surgical complication 4. Time-to-Event
outcomes:
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta‐analysis
1. Infection 2. Neutropenic Disorder 3. Vomiting 4. Febrile Neutropenia 5. Hiccups 6. Death 7. Clinical Resolution 8. Nausea 9. Infusion Site Reactions 10. Adverse Event 11. Health-Related Quality of Life
outcomes:
Perioperative systemic nonsteroidal anti‐inflammatory drugs (NSAIDs) in women undergoing breast surgery
1. Postoperative Pain 2. Breast Hematoma
outcomes:
Music interventions for improving psychological and physical outcomes in people with cancer
1. Adjustment Reaction With Physical Symptoms 2. Psychological Symptom
outcomes:
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation
1. All Cause Mortality 2. Minor Bleed 3. Death 4. Pulmonary Embolism 5. Major Bleed 6. Deep Venous Thrombosis
outcomes:
Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer
1. Catheter Related Infection 2. Catheter Sepsis
outcomes:
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
1. Death
outcomes:
School‐based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6 to 18
1. Body Mass Index 2. Screen Time 3. Systolic Blood Pressure 4. Diastolic Blood Pressure 5. Physical Activity Level
outcomes:
Roux‐en‐Y versus Billroth‐I reconstruction after distal gastrectomy for gastric cancer
1. Biliary Anastomotic Leak
outcomes:
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma
1. All Cause Mortality 2. Serious Adverse Event 3. Recurrent Tumor 4. Health-Related Quality of Life 5. Cancer
outcomes:
Interventions targeted at women to encourage the uptake of cervical screening
1. Screening Procedure
outcomes:
High‐dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma
1. Overall Survival 2. Event-Free Survival 3. Poisoning 4. Quality Adjusted Life Years
outcomes:
Partial breast irradiation versus whole breast radiotherapy for early breast cancer
1. Disease-Free Survival 2. Simple mastectomy 3. Finding Of Appearance Of Breast 4. Death 5. Recurrence free survival 6. Toxicity Due To Radiotherapy 7. Cosmetics 8. Metastasis 9. Fibrosis Of Subcutaneous Tissue 10. Survival
outcomes:
Hydromorphone for cancer pain
1. Vomiting 2. Death 3. Nausea 4. Constipation 5. Pain Relief 6. Pain Intensity 7. Patient-Reported Outcome
outcomes:
Degarelix for treating advanced hormone‐sensitive prostate cancer
1. Serious Adverse Event 2. Cardiovascular Event 3. Overall Survival 4. Quality of Life 5. Survival 6. Injection Site Pain 7. Cancer
outcomes:
Physical therapy interventions, other than general physical exercise interventions, in children and adolescents before, during and following treatment for cancer
1. Quality of Life 2. Adverse Event
outcomes:
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer
1. Bowel resection 2. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 3. Serious Adverse Event 4. Overall Survival 5. Progression-Free Survival 6. Quality of Life 7. Death 8. Stoma 9. No Evidence Of Neoplasm
outcomes:
Protons versus photons for the treatment of chordoma
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Disease Recurrence 3. Death 4. Patient compliance 5. Local Control Of Neoplasm
outcomes:
Intravesical gemcitabine for non‐muscle invasive bladder cancer
1. All Cause Mortality 2. Disease Progression 3. Quality of Life 4. Death 5. Adverse Event 6. Time-to-Event
outcomes:
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
1. Objective Response Rate 2. Overall Survival 3. Progression-Free Survival 4. Quality of Life 5. Death 6. Adverse Event 7. Tumor Progression 8. Health-Related Quality of Life
outcomes:
PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
1. Short Form Health Survey - 36 2. Progression-Free Survival 3. Overall Survival 4. Quality of Life 5. Adverse Event 6. Therapeutic Response
outcomes:
First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
1. Overall Survival 2. Progression-Free Survival
outcomes:
Exercise for cancer cachexia in adults
1. Body Mass Index 2. Fatigue 3. Exercise Capacity 4. Adverse Event 5. Patient compliance 6. Muscle Strength 7. Health-Related Quality of Life
outcomes:
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
1. Overall Survival 2. Adverse Event
outcomes:
Paravertebral anaesthesia with or without sedation versus general anaesthesia for women undergoing breast cancer surgery
1. Pain Scale 2. Death 3. Quality of care
outcomes:
Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Quality of Life 3. Death
outcomes:
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen
1. Uterine fibroid 2. Endometrial Cancer 3. Polyp Of Corpus Uteri 4. Endometrial Hyperplasia 5. Death 6. Abnormal Vaginal Bleeding 7. Locally Recurrent Breast Cancer
outcomes:
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
1. Serious Adverse Event 2. Disease Progression 3. Quality of Life 4. Death 5. Prostate Cancer 6. Withdrawal Due To Adverse Events 7. Time-to-Event
outcomes:
Body weight management in overweight and obese breast cancer survivors
1. Recurrent Tumor 2. Overall Survival 3. Breast Cancer
outcomes:
Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis
1. Pain 2. Finding Of Response To Pain 3. Adverse Event 4. Osteonecrosis Of Jaw Due To Drug
outcomes:
Platinum‐containing regimens for triple‐negative metastatic breast cancer
1. Leukopenia 2. Anemia 3. Vomiting 4. Progression-Free Survival 5. Overall Survival 6. Death 7. Treatment discontinued 8. Nausea 9. Hair loss 10. Nephrotoxicity
outcomes:
Targeted therapy for metastatic renal cell carcinoma
1. Serious Adverse Event 2. Overall Survival 3. Progression-Free Survival
outcomes:
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
1. All Cause Mortality 2. Venous Thrombosis 3. Major Bleed
outcomes:
The effectiveness and cost‐effectiveness of hospital‐based specialist palliative care for adults with advanced illness and their caregivers
1. Pain 2. Morbidity Index 3. Costs and Cost Analysis 4. Evaluation Of Satisfaction With Healthcare 5. Quality of Life 6. Caregiver Role Strain 7. Discussion About Preferred Place Of Death
outcomes:
Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
1. Erectile Dysfunction 2. Urinary Continence 3. Serious Adverse Event 4. International Index Of Erectile Function 5. Surgical Margin Finding 6. Recurrence free survival
outcomes:
Helicobacter pylori eradication for the prevention of gastric neoplasia
1. Squamous Cell Carcinoma Of Esophagus 2. All Cause Mortality 3. Gastric Cancer
outcomes:
Radical prostatectomy versus deferred treatment for localised prostate cancer
1. Death
outcomes:
Telephone interventions for symptom management in adults with cancer
1. Fatigue Impact Scale 2. Emotional Distress 3. Pain 4. Hospital Anxiety And Depression Scale 5. Lung cancer 6. Fatigue 7. Depressive symptoms 8. Nausea 9. Anxiety 10. Sexuality Related Problem 11. Profile Of Mood States
outcomes:
Surgery versus radical endotherapies for early cancer and high‐grade dysplasia in Barrett's oesophagus
1. Overall Survival 2. Tumor Progression
outcomes:
External beam radiation dose escalation for high grade glioma
1. Death 2. Adverse Event
outcomes:
Physical activity interventions for disease‐related physical and mental health during and following treatment in people with non‐advanced colorectal cancer
1. Mental Health Assessment Status 2. Adverse Event 3. Functional ability
outcomes:
Interventions for the management of malignant pleural effusions: a network meta‐analysis
1. Repeat surgery 2. Pleural Fluid Examination 3. Symptom recurrence
outcomes:
Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer
1. Death 2. Recurrence free survival
outcomes:
Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer
1. Disease-Free Survival 2. Recurrent contralateral breast cancer 3. Overall Survival 4. Quality of Life 5. Poisoning 6. Hot flush
outcomes:
Drugs for preventing lung cancer in healthy people
1. Gastrointestinal Symptom 2. Yellow Skin 3. All Cause Mortality 4. Alopecia 5. Hemorrhagic Cerebral Infarction 6. Lung cancer 7. Death 8. Calcium Renal Calculus 9. Dermatitis 10. Adverse Event 11. Serum Calcium 12. Cancer
outcomes:
Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. Aromatase Inhibitors 2. Pain 3. Safety Finding 4. Musculoskeletal Symptom 5. Adverse Event 6. Health-Related Quality of Life
outcomes:
Hormone replacement therapy after surgery for epithelial ovarian cancer
1. Quality of Life 2. Death
outcomes:
Drug therapy for delirium in terminally ill adults
1. Delirium 2. Agitated Behaviour Scale 3. Extrapyramidal Sign 4. Agitated 5. Adverse Event
outcomes:
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
1. Hearing impairment 2. Event-Free Survival 3. Overall Survival 4. Quality of Life 5. Death 6. Tinnitus 7. Drug toxicity 8. Therapeutic Response 9. Cancer
outcomes:
Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas
1. Death
outcomes:
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
1. Thrombocytopenia 2. Neurotoxicity 3. Toxicity Renal 4. Overall Survival 5. Death 6. Survival 7. Health-Related Quality of Life 8. Therapeutic Response
outcomes:
Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Serious Adverse Event 3. Recurrent Tumor 4. Quality of Life 5. Death 6. Tumor Progression 7. Time-to-Event
outcomes:
Interval brain imaging for adults with cerebral glioma
1. Death
outcomes:
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
1. Swelling 2. Vaginal Cancer 3. Cervical Cancer 4. Anal cancer 5. All Cause Mortality 6. Penile Intraepithelial Neoplasia 7. Serious Adverse Event 8. Pain 9. Penile cancer 10. Vulval cancer 11. Anal Intraepithelial Neoplasia 12. Vulval Intraepithelial Neoplasia (vin) 13. Vaginal Intraepithelial Neoplasia 14. Erythema 15. Cervical Intraepithelial Neoplasia 16. Anogenital Warts
outcomes:
Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors
1. Costs and Cost Analysis 2. Recurrent Tumor 3. Overall Survival 4. Depression 5. Anxiety 6. Health-Related Quality of Life
outcomes:
Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
1. Surgical Site Infection 2. Healthcare costs 3. Readmission 4. Allergic Reaction To Antibiotics
outcomes:
Follow‐up strategies for patients treated for non‐metastatic colorectal cancer
1. Relapse 2. Procedure On Colon 3. Overall Survival 4. Event-Free Survival 5. Intestinal Perforation 6. Colorectal Cancer 7. Death 8. Survival 9. Recurrent Cancer
outcomes:
Taxanes for adjuvant treatment of early breast cancer
1. Overall Survival
outcomes:
Hypofractionation for clinically localized prostate cancer
1. Genitourinary Tract Problem 2. Disease-Free Survival 3. Relapse 4. Overall Survival 5. Acute Radiation Toxicity 6. Recurrence free survival 7. Prostate Cancer 8. Gastrointestinal Toxicity 9. Survival
outcomes:
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
1. Venous Thrombosis 2. Death 3. Complication 4. Haemorrhage 5. Deep Venous Thrombosis
outcomes:
Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma
1. Quality of Life 2. Cognitive impairment
outcomes:
Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of hospital stay and postoperative complications
1. Postoperative Complication 2. Pneumonia 3. Abdominal abscess 4. Length Of Stay 5. Gastrointestinal Anastomotic Leak 6. Wound Infection
outcomes:
Psychosocial interventions for informal caregivers of people living with cancer
1. Caregiver 2. Quality of Life 3. Depression 4. Anxiety 5. Health Status 6. Adverse Event
outcomes:
Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
1. Dyspnea 2. Safety Finding 3. Exercise Capacity 4. Health-Related Quality of Life
outcomes:
Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
1. All Cause Mortality 2. Serious Adverse Event 3. Quality of Life 4. Heart Failure 5. Fatigue 6. Death 7. Event 8. Prostate Cancer 9. Skeleton 10. Global Assessment 11. Time-to-Event
outcomes:
Perioperative nutrition for the treatment of bladder cancer by radical cystectomy
1. Postoperative Complication 2. Length Of Stay 3. Death
outcomes:
Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
1. Serious Adverse Event 2. Quality of Life 3. Death 4. Urothelial Carcinoma 5. Adverse Event 6. Time-to-Event 7. Bladder cancer recurrent
outcomes:
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
1. Postoperative Complication 2. Overall Survival 3. Death 4. Bladder Cancer 5. Time-to-Event 6. Bladder cancer recurrent
outcomes:
Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer
1. Toxicity Renal 2. Vomiting 3. Hearing impairment 4. Event-Free Survival 5. Overall Survival 6. Quality of Life 7. Cardiotoxicity 8. Tinnitus 9. Adverse Event 10. Therapeutic Response 11. Cancer
outcomes:
Risk‐reducing medications for primary breast cancer: a network meta‐analysis
1. Poisoning 2. Breast Cancer
outcomes:
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
1. Overall Survival 2. Progression-Free Survival 3. Event-Free Survival 4. Death 5. Adverse Event 6. Drug toxicity 7. Health-Related Quality of Life
outcomes:
Robotic versus open radical cystectomy for bladder cancer in adults
1. Postoperative Complication 2. Blood Transfusion 3. Quality of Life 4. Bladder Cancer 5. Hospitalization 6. Time-to-Event 7. Bladder cancer recurrent
outcomes:
Mindfulness‐based stress reduction for women diagnosed with breast cancer
1. Overall Survival 2. Quality Of Sleep 3. Quality of Life 4. Fatigue 5. Depression 6. Death 7. Anxiety 8. Adverse Event
outcomes:
Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Carer Support Needs Assessment Tool 3. Hospital Anxiety And Depression Scale 4. Quality of Life 5. Supportive care 6. Short Form Social Support Questionnaire 7. Distress 8. Health-Related Quality of Life 9. Beck Depression Inventory
outcomes:
Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event
1. Treatment Failure 2. Death
outcomes:
Palliative interventions for controlling vaginal bleeding in advanced cervical cancer
1. Anemia 2. Death
outcomes:
Psychological interventions for parents of children and adolescents with chronic illness
1. Functional Assessment Measure 2. Depression 3. Anxiety 4. Functional ability 5. Symptom control therapy 6. Parenting behaviour 7. Patient-Reported Outcome
outcomes:
Intralesional treatment versus wide resection for central low‐grade chondrosarcoma of the long bones
1. Death
outcomes:
Non‐invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
1. Postoperative pulmonary complication 2. Death 3. Duration Of Hospital Stay 4. Intubation 5. Intensive Care
outcomes:
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
1. Vaginal Dryness 2. Premature ovarian insufficiency 3. Pregnancy 4. Hot flush 5. Retained Menstruation
outcomes:
Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults
1. Treatment Withdrawal 2. Stai - Spielberger State-trait Anxiety Inventory 3. Borg Scale 4. Hospital Anxiety And Depression Scale 5. Visual Analog Scale 6. Adverse Event 7. Respiratory Distress 8. Patient Satisfaction
outcomes:
Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment
1. Infection 2. Pain 3. Postsurgical Lymphedema 4. Heavy Feeling 5. Functional ability 6. Lymphedema Due To Radiation
outcomes:
Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults
1. All Cause Mortality 2. Serious Adverse Event 3. Therapeutic Response
outcomes:
Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa)
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Clean Intermittent Self-catheterization 3. Quality of Life 4. Death
outcomes:
De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV‐positive oropharyngeal carcinoma
1. Disease-Free Survival 2. Overall Survival 3. Voice Finding 4. Death 5. Finding Related To Ability To Swallow 6. Voice Handicap Index
outcomes:
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery
1. Physical fitness
outcomes:
Anti‐angiogenic therapy for high‐grade glioma
1. Overall Survival 2. Progression-Free Survival 3. Death
outcomes:
Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer
1. Stomatitis 2. Nausea And Vomiting 3. Overall Survival 4. Progression-Free Survival 5. Quality of Life 6. Death 7. Diarrhoea 8. Toxicity Due To Chemotherapy 9. Patient compliance
outcomes:
Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer
1. Effects Of Chemotherapy 2. Adverse Effect Of Radiation Therapy
outcomes:
Laparoscopy versus laparotomy for the management of early stage endometrial cancer
1. Recurrence free survival 2. Death
outcomes:
Extended‐field radiotherapy for locally advanced cervical cancer
1. Disease Recurrence 2. Death
outcomes:
Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
1. Serious Adverse Event 2. Quality of Life 3. Progression Of Prostate Cancer 4. Death 5. Prostate Cancer 6. Withdrawal Due To Adverse Events 7. Adverse Event 8. Time-to-Event
outcomes:
Epidermal growth factor receptor blockers for the treatment of ovarian cancer
1. Rash 2. Anemia 3. Nausea And Vomiting 4. Overall Survival 5. Progression-Free Survival 6. Quality of Life 7. Hypokalemia 8. Death 9. Fatigue 10. Diarrhoea 11. Drug toxicity
outcomes:
Exercise for reducing falls in people living with and beyond cancer
1. Falls 2. Fatigue 3. Balance 4. Muscle Strength 5. Flexibility 6. Walk Test
outcomes:
Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer
1. Lymphedema 2. Overall Survival 3. Progression-Free Survival 4. Death 5. Local Recurrence Of Malignant Tumor Of Cervix
outcomes:
Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma
1. Recurrent Tumor 2. Surgical complication 3. Rectal resection 4. Quality of Life 5. Death 6. Sepsis
outcomes:
Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults
1. Decreased Nausea And Vomiting 2. Serious Adverse Event 3. Drug Therapy 4. Fatigue 5. Sleepiness 6. Patient's Global Evaluation 7. Patient Satisfaction
outcomes:
Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Assessment Of Quality Of Life 3. Diarrhea 4. Quality of Life 5. Severe Diarrhea 6. Common Terminology Criteria For Adverse Events
outcomes:
Immunonutrition for patients undergoing surgery for head and neck cancer
1. All Cause Mortality 2. Duration Of Hospital Stay 3. Fistula 4. Enteral Feeding Intolerance 5. Adverse Event 6. Wound Infection
outcomes:
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations
1. Death
outcomes:
Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis
1. Death 2. Adverse Event 3. Survival
outcomes:
Virtual reality simulation training for health professions trainees in gastrointestinal endoscopy
1. Mucosal Finding 2. Discomfort 3. Competence 4. Duration Of Surgery 5. Complication 6. Endoscopy
outcomes:
Home parenteral nutrition for people with inoperable malignant bowel obstruction
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Quality of Life 3. Survival
outcomes:
Communication skills training for healthcare professionals working with people who have cancer
1. Communication skills 2. Communication Skills Training
outcomes:
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
1. Pembrolizumab 2. Serious Adverse Event 3. Quality of Life 4. Death 5. Withdrawal Due To Adverse Events 6. Time-to-Event 7. Therapeutic Response
outcomes:
Anticoagulation for perioperative thromboprophylaxis in people with cancer
1. Intraoperative Hemorrhage 2. All Cause Mortality 3. Transfusion 4. Symptomatic Recurrent Deep Venous Thrombosis 5. Repeat surgery 6. Blood Volume Estimation 7. Minor Bleed 8. Wound Hematoma 9. Pulmonary Embolism 10. Heparin-induced Thrombocytopenia 11. Major Bleed
outcomes:
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery
1. Radiologic Finding
outcomes:
Anticoagulation for people with cancer and central venous catheters
1. Catheter Related Infection 2. Thrombocytopenia 3. Catheter Thrombosis 4. Accidental Removal Of Catheter 5. All Cause Mortality 6. Minor Bleed 7. Symptomatic Recurrent Venous Thrombosis 8. Pulmonary Embolism 9. Major Bleed
outcomes:
Primary cryotherapy for localised or locally advanced prostate cancer
1. Bowel Finding 2. Serious Adverse Event 3. Repeat surgery 4. Treatment Failure 5. Quality of Life 6. Death 7. Urinary System Finding 8. Prostate Cancer 9. Time-to-Event 10. Sexual function
outcomes:
Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction
1. All Cause Mortality 2. Re-establishment of oral intake 3. Clinical Resolution 4. Duration Of Hospital Stay 5. Adverse Event 6. Survival 7. Health-Related Quality of Life
outcomes:
Hormone replacement therapy for women previously treated for endometrial cancer
1. At Risk Of Malignancy 2. Disease Recurrence 3. Death 4. Clinical Improvement
outcomes:
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
1. Cervical Intraepithelial Neoplasia Grade 1 2. Invasive Cervical Cancer 3. Adverse Event
outcomes:
Hyperbaric oxygenation for tumour sensitisation to radiotherapy
1. Disease Recurrence 2. Treatment Failure 3. Death
outcomes:
Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas
1. All Cause Mortality 2. Serious Adverse Event 3. Quality of Life 4. General Signs And Symptoms
outcomes:
Breast surgery for metastatic breast cancer
1. Quality of Life 2. Death
outcomes:
Oral water soluble contrast for malignant bowel obstruction
1. Hypersensitivity Reaction 2. Vomiting 3. Gastrointestinal findings 4. Aspiration Pneumonia 5. Clinical Resolution 6. Duration Of Hospital Stay 7. Nausea 8. Abdominal Pain 9. Malignant Bowel Obstruction 10. Survival
outcomes:
Ghrelin for the management of cachexia associated with cancer
1. Food intake 2. Body weight 3. Adverse Event
outcomes:
Non‐steroidal anti‐inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia
1. Cervical Intraepithelial Neoplasia Grade 1
outcomes:
Influenza vaccines in immunosuppressed adults with cancer
1. Death
outcomes:
Physical activity for women with breast cancer after adjuvant therapy
1. Quality of Life 2. Death 3. Depression 4. Fatigue 5. Anxiety 6. Emotional stress
outcomes:
Selenium for preventing cancer
1. Death 2. Cancer
outcomes:
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
1. Disease Progression 2. Quality of Life 3. Disease Related State 4. Neurological Deficit 5. Death 6. Adverse Event 7. Medication Regimen Behaviour Finding 8. Clinical Improvement
outcomes:
Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers
1. Gastrointestinal Symptom 2. Gastrointestinal Irritation 3. Quality of Life
outcomes:
Gefitinib for advanced non‐small cell lung cancer
1. Overall Survival 2. Progression-Free Survival 3. Poisoning
outcomes:
Bisphosphonates for advanced prostate cancer
1. Primary Malignant Neoplasm Of Prostate Metastatic To Bone 2. Disease Progression 3. Finding Of Response To Pain 4. Quality of Life 5. Death 6. Renal Impairment 7. Nausea 8. Aseptic Necrosis Of Bone Of Jaw 9. Event 10. Skeleton
outcomes:
Tumour bed boost radiotherapy for women after breast‐conserving surgery
1. Disease-Free Survival 2. Disease Recurrence 3. Overall Survival 4. Toxicity Due To Radiotherapy 5. Recurrence free survival 6. Death 7. Cosmetics 8. Local Control Of Neoplasm
outcomes:
Closure methods for laparotomy incisions for preventing incisional hernias and other wound complications
1. Incisional Hernia 2. Fistula 3. Wound Dehiscence 4. Wound Infection
outcomes:
Bisphosphonates and other bone agents for breast cancer
1. Skeletal Injury NOS 2. Adverse Drug Reaction 3. Bone Pain 4. Overall Survival 5. Secondary malignant neoplasm of bone 6. Quality of Life 7. Death 8. Fracture 9. Osteonecrosis Of Jaw Due To Bisphosphonate 10. Recurrent Cancer
outcomes:
Lymphadenectomy for the management of endometrial cancer
1. Death
outcomes:
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases
1. Karnofsky Scale 2. Death
outcomes:
Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy
1. Pancreatic Fistula
outcomes:
Intravesical electromotive drug administration for non‐muscle invasive bladder cancer
1. Serious Adverse Event 2. Recurrent Tumor 3. Quality of Life 4. Invasive Bladder Cancer 5. Tumor Progression 6. Survival 7. Time-to-Event
outcomes:
Laparoscopic and robotic‐assisted versus open radical prostatectomy for the treatment of localised prostate cancer
1. Surgical complication 2. Overall Survival 3. Recurrence free survival 4. Urinary System Finding 5. Prostate Cancer 6. Survival 7. Sexual function